Eli Lilly and Company’s Post

"𝐌𝐞𝐭𝐟𝐨𝐫𝐦𝐢𝐧 𝐂𝐨𝐧𝐭𝐫𝐚𝐢𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐑𝐞𝐧𝐚𝐥 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧" Do you the Reason 😳 ⁉ .If not have a Read, 👇 ✔ Metformin is #Contraindicated in patients with renal dysfunction because of risk of "𝑳𝒂𝒄𝒕𝒊𝒄 𝑨𝒄𝒊𝒅𝒐𝒔𝒊𝒔".🚀 ✔ The 𝐩𝐚𝐭𝐡𝐨𝐩𝐡𝐲𝐬𝐢𝐨𝐥𝐨𝐠𝐲 of lactic acidosis from #metformin is likely due to 𝒊𝒏𝒉𝒊𝒃𝒊𝒕𝒊𝒐𝒏 𝒐𝒇 𝒈𝒍𝒖𝒄𝒐𝒏𝒆𝒐𝒈𝒆𝒏𝒆𝒔𝒊𝒔 𝒃𝒚 𝒃𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝒑𝒚𝒓𝒖𝒗𝒂𝒕𝒆,the first step of gluconeogenesis, which converts pyruvate to oxaloacetate. Blocking this enzyme leads to accumulation of lactic acid. 𝑩𝒊𝒈𝒖𝒂𝒏𝒊𝒅𝒆𝒔 𝒂𝒍𝒔𝒐 𝒅𝒆𝒄𝒓𝒆𝒂𝒔𝒆 𝒉𝒆𝒑𝒂𝒕𝒊𝒄 𝒎𝒆𝒕𝒂𝒃𝒐𝒍𝒊𝒔𝒎 𝒐𝒇 𝒍𝒂𝒄𝒕𝒂𝒕𝒆 and have a negative ionotropic effect on the heart, both of which #elevate lactate levels. ♻♻ ✔ American Diabetes Association (ADA) recommends #metformin as the initial Drug of Choice for type 2 diabetes.It can be used alone or in combination other oral agents or #insulin .💯 ✔ Metformin main 𝑴𝒆𝒄𝒉𝒂𝒏𝒊𝒔𝒎 𝒐𝒇 𝒂𝒄𝒕𝒊𝒐𝒏 is reduction of #hepatic gluconeogenesis.It also slows intestinal absorption of sugars and and improves peripheral #glucose uptake and utilization.💊⚖💊 𝑯𝒐𝒑𝒆 𝒚𝒐𝒖 𝒈𝒐𝒕 𝒚𝒐𝒖𝒓 𝒂𝒏𝒔𝒘𝒆𝒓 𝒅𝒐 𝒍𝒊𝒌𝒆 𝒂𝒏𝒅 #𝒔𝒉𝒂𝒓𝒆 𝒘𝒊𝒕𝒉 𝒚𝒐𝒖𝒓 #𝒏𝒆𝒕𝒘𝒐𝒓𝒌 👨⚕️👨⚕️. Reference, 1️⃣ https://lnkd.in/dekD9CTm 2️⃣ https://lnkd.in/dn8hXeqs 3️⃣ https://lnkd.in/ddXpahD9 #medicalwriting #healthwriting #researchwriting #healthcare

Glen Tullman writes an article as part of the World Economic Forum Annual Meeting in Davos this past week, on the obesity pandemic, why GLP-1 drugs should only be a part of the solution, and the need to embrace a high-quality, comprehensive strategy. GLP-1 medications ‘…should only be part of a comprehensive and sustainable solution and not used in a silo…’ with an intent to ‘…prioritize whole-person, high-quality care.’ The article advises employers to consider obesity medicine specialists, clinical appropriateness of care, long-term healthy weight, and cost-efficient care, for them to deliver high-quality, longitudinal weight management solutions, toward a healthier and happier self. All good – though we need to advance beyond weight loss as the metric of success, toward a reduction in chronic disease burden. And further, to consider health inequities that abound across the globe, for those who are more disproportionately affected by obesity; coupled with the troubling paradox that they are also less likely to receive appropriate treatment for their disease. https://lnkd.in/eAQgb72n

❓Question: Is the weight-loss drug craze driving up patient out-of-pocket costs? Answer, according to IQVIA Institute research: Patient out-of-pocket costs in aggregate grew by $5Bn in 2023, with growing GLP-1 agonist use in diabetes and obesity contributing significantly. Learn more about the impact of the growing us of GLP-1 agonists in the Use of Medicines in the U.S. 2024 report by downloading it here: https://lnkd.in/eVytWujs #PharmaSpending

The Rise of Ozempic: How Semaglutide Products Are Transforming the Weight Loss Market How groundbreaking medications like Ozempic are shaping the future of weight management and diabetes care https://lnkd.in/eXQnDski

Recent research see potential in CBD as a promising force in oral health enhancement, extending beyond its conventional applications such as: 1. Anti-Inflammatory Effects: CBD's anti-inflammatory properties target gum inflammation, potentially managing associated conditions and fostering overall oral well-being. 2. Antibacterial Properties: Demonstrating antibacterial potential, CBD may address oral pathogens, promoting a healthier oral microbiome and preventing infections. 3. Potential for Periodontal Health: Emerging research hints at CBD's role in gum-related conditions, supporting a preventive approach to periodontal diseases. 🚫 Note: CBD is not a treatment for specific dental illnesses. Always seek personalized advice from healthcare professionals for optimal guidance. Follow PCC for more updated CBD insights! #cbd #CBDandDentalWellness #OralHealthEnhancement #AntiInflammatoryCBD #CBDforOralMicrobiome #PeriodontalHealth #CBDResearch #cbdwellness #CBDhealth #medicalexperts #physicianscbdcouncil #cbdproducts #cbdcommunity #cannabiseducation #thc #cbdc #cbdcs #cbdt 

What you should know about obesity and metabolic health this week: ▶ Biocon Ltd. is leading India’s push to weight loss medications as patents lapse, unleashing generic supply for the global weight-loss market, from Bloomberg. ▶ STAT News reports European regulators ‘…have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.’ ▶ ‘I'm a doctor on Ozempic – it's effective under one condition…’ says President and CEO of Philadelphia College of Osteopathic Medicine, Jay S. Feldstein, DO, in a deeply personal Newsweek article. ▶ The New England Journal of Medicine (NEJM Group) published on the positive impact of Novo Nordisk’s semaglutide drug on people with obesity-related heart failure and type 2 diabetes. ▶ The New York Times reports How Ozempic Turned a 1970s Hit Into an Inescapable Jingle. ▶ Christopher C. Thompson, MD MSc FASGE FACG AGAF, writes in JAMA Network Open on the cost-effectiveness viability of semaglutide compared with endoscopic sleeve gastroplasty [ESG]. Read these full stories and more in our newsletter - link in the comments. #obesity #metabolichealth #letstalkaboutobesity

📊 Weight Regain After Discontinuing Eli Lilly and Company's Zepbound: New Data 🚫 Patients taking Eli Lilly’s weight loss drug Zepbound experienced substantial weight regain, nearly half of the lost weight within a year of discontinuation, according to recent data published in JAMA. The study, funded by Eli Lilly, involved an 88-week assessment, highlighting the need for ongoing weekly injections to sustain significant weight loss. The findings contributed to a decline of over 2% in Eli Lilly's stock. This underscores the challenges and considerations associated with maintaining weight loss after stopping certain obesity treatments. #weightloss #zepbound #obesitytreatment #elililly

New Articles in #Diabetes and #Metabolic Syndrome: #Clinical #Research/#Reviews (IMPACT FACTOR, 10, Ranked #1 Journal for Diabetes/Endo in #Asia.) The #Burden of #CardiovascularDisease attributable to High #Fasting #Plasma #Glucose：Findings From the #GlobalBurdenofDiseaseStudy 2019 Dong et al. https://lnkd.in/d7PKt4mJ

Did you know that Ketamine, a powerful anesthetic, may have an impact on blood pressure? Our latest article explores the science behind this lesser-known facet of the widely used drug. Discover why this research could be a game changer for patients struggling with hypertension. Can't wait to hear your insights on this fascinating topic. Visit https://lnkd.in/eqcwyJx4 now! #Ketamine #BloodPressure #HealthResearch #Hypertension #PharmaceuticalScience4346

The answer to yesterday’s #ClinicalChallenge question is: C. Glucagon-like peptide 1-based therapies (tirzepetide, semaglutide) for the treatment of obesity result in substantial weight loss, but stopping treatment results in weight regain. Most individuals with obesity who opt for pharmacotherapy will require long-term treatment for weight loss maintenance. View the related Practice Changing Update in #UpToDate: https://ow.ly/AcLr50TsfbI #meded